文献速递免疫规划

VARIVAX®冷藏稳定剂型的双盲随机对照多中心安全性与免疫原性研究

A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®.
PubMed 文献 · Vaccine · 2018-08-23

本研究为双盲、随机、多中心研究,纳入12至23月龄健康儿童,比较VARIVAX®冷藏稳定剂型(8000 PFU组N=320、25000 PFU组N=315)与冷冻剂型(10000 PFU组N=323)同时接种M-M-RII®后的安全性与免疫原性。结果显示冷藏稳定剂型耐受性良好,不良经历发生率三组相似,未报告疫苗相关严重不良经历;接种6周后水痘抗体滴度≥5 gpELISA单位的受试者百分比及麻疹、腮腺炎、风疹血清转化率和GMT与冷冻剂型相当。结论为冷藏稳定剂型的安全、耐受和免疫原性特征与冷冻剂型相似。

要点

  • 冷藏稳定剂型VARIVAX®不良经历发生率与冷冻剂型相似,未报告疫苗相关严重不良经历。
  • 接种6周后水痘抗体滴度≥5 gpELISA单位的受试者百分比冷藏剂型与冷冻剂型相似。
  • 同时接种M-M-RII®后麻疹、腮腺炎、风疹血清转化率和GMT与冷冻剂型相当。

核心结论

  • 冷藏稳定剂型水痘疫苗的安全、耐受和免疫原性特征与冷冻剂型相似。

研究设计与样本

  • 双盲、随机、多中心研究,纳入12至23月龄健康儿童,接种冷藏稳定剂型VARIVAX®8000 PFU(N=320)或25000 PFU(N=315),或冷冻剂型VARIVAX®10000 PFU(N=323),均同时接种M-M-RII®。
  • 接种后随访42天记录不良经历,接种6周后评价免疫原性。

主要发现

  • 冷藏稳定剂型VARIVAX®总体耐受性良好,三组不良经历发生率相似。
  • 任何疫苗剂型均未报告疫苗相关严重不良经历。
  • 接种6周后,两种冷藏稳定剂型的水痘抗体滴度≥5 gpELISA单位的受试者百分比与冷冻剂型相似。
  • 冷藏稳定剂型或冷冻剂型与M-M-RII®同时接种后,麻疹、腮腺炎、风疹的血清转化率和GMT相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: VARIVAX® (varicella virus vaccine, live Oka/Merck, Merck & Co., Inc., Kenilworth, NJ, USA) was originally licensed as a frozen formulation. A refrigerator-stable formulation of VARIVAX was subsequently developed to allow for increased availability of the product around the world. The objective of this study (V210-051) was to demonstrate that the safety, tolerability and immunogenicity profile of the refrigerator-stable formulation of VARIVAX was similar to the frozen formulation. METHODS: In this double-blind, randomized, multicenter study, healthy 12- to 23-month-old children with negative vaccination and clinical histories for measles, mumps, rubella, varicella, and zoster were vaccinated with either a refrigerator-stable formulation of VARIVAX (at two dosage levels; 8000 PFU [N = 320] or 25,000 PFU [N = 315]) or the frozen formulation of VARIVAX (10,000 PFU, N = 323) given concomitantly with M-M-RII® (measles, mumps, and rubella virus vaccine live, Merck & Co., Inc., Kenilworth, NJ, USA). Children were followed for 42 days after vaccination for adverse experiences. Immunogenicity was evaluated 6 weeks after vaccination. RESULTS: The refrigerator-stable formulation of VARIVAX was generally well tolerated. The incidence of adverse experiences was similar between all three groups. No vaccine-related serious adverse experiences were reported with any of the vaccine formulations. The immune response (percentage of subjects with varicella antibody titers ≥5 gpELISA units) for both refrigerator-stable formulations of VARIVAX at 6 weeks postvaccination was similar to that of the frozen formulation. Administration of either refrigerator-stable formulation of VARIVAX with M-M-RII yielded seroconversion rates and GMTs for measles, mumps and rubella that were comparable to those achieved after administration of the frozen formulation of VARIVAX with M-M-RII. CONCLUSION: The safety, tolerability, and immunogenicity profile of the refrigerator-stable varicella vaccine was similar to that of the frozen formulation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Reisinger KS, Richardson E, Malacaman EA, et al. A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®. Vaccine. 2018. PMID: 30146405. doi:10.1016/j.vaccine.2018.01.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。